Development of 2023 ACR/EULAR Antiphospholipid Syndrome Classification Criteria, Phase III-A/B Report: Defining and Structuring the Clinical and Laboratory Domains.

Date publication

novembre 2025

Journal

Current rheumatology reports

Auteurs

Membres identifiés du Cancéropôle Est :
Pr GUILLEMIN Francis

Tous les auteurs :
Barbhaiya M, Zuily S, Amigo MC, Avcin T, Bertolaccini ML, Branch DW, de Jesus GR, Devreese KMJ, Frances C, Garcia D, Guillemin F, Levine SR, Levy RA, Lockshin MD, Ortel TL, Seshan SV, Tektonidou MG, Wahl D, Willis R, Hendry A, Naden R, Costenbader KH, Erkan D,

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/41296194

Résumé

An international multi-disciplinary initiative resulted in the development of 2023 ACR/EULAR Antiphospholipid Syndrome (APS) Classification Criteria to identify patients with high likelihood of APS for research. Phase I/II resulted in 27 candidate criteria organized into six clinical and laboratory domains. Here, we summarize early Phase III efforts to better define and structure candidate criteria within clinical and laboratory domains.

Mots clés

Antiphospholipid syndrome, Classification criteria, Methodology

Référence

Curr Rheumatol Rep. 2025 11 26;27(1):41